Further SAR in the new antitumor 1-amino-substituted gamma-carbolines and 5H-benzo[e]pyrido[4,3-b]indoles series
- PMID: 1319166
Further SAR in the new antitumor 1-amino-substituted gamma-carbolines and 5H-benzo[e]pyrido[4,3-b]indoles series
Abstract
Using previously described techniques, various new 1-amino-substituted 5H-pyrido[4,3-b]indoles (gamma-carbolines, gamma-C) and 5H-benzo[e]pyrido[4,3-b]indoles (BPI) have been synthesized and evaluated. For known compounds containing a 1-[(dimethylamino)propyl] group, 1a and 1b in the gamma-C series and 2 in the BPI series are the most active. Studies with newly synthesized derivatives show that: (i) in the gamma-C series, the 4-unsubstituted-8-hydroxy-compound was inactive, whereas the 4-unsubstituted-9-hydroxy-5H-benzo[e]pyrido[4,3-b]indole is active; (ii) the 4-ethyl-8-hydroxy-5H-pyrido[4,3-b]indole derivative retains antitumor properties, but the 1-amino-substituted 4-ethyl-9-hydroxy-5H-benzo[e]pyrido[4,3-b]indole analog is devoid of biological activity; (iii) in the 5H-benzo[e]pyrido[4,3-b]indole series, the displacement of a hydroxyl group from the 9- to 10-position leads to inactive compounds. Based on the structural analogies, these results were unexpected because the same substituents on the 4-position lead to different biological properties in the two series.
Similar articles
-
Synthesis and antitumor properties of new 4-methyl-substituted- pyrido[4,3-b]indoles (gamma-carbolines).Anticancer Drug Des. 1992 Jun;7(3):219-33. Anticancer Drug Des. 1992. PMID: 1610481
-
Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.Cancer Res. 1993 Dec 15;53(24):5987-93. Cancer Res. 1993. PMID: 8261412
-
Synthesis, properties and biological evaluation of substituted furo[3,2-e] and pyrano[3,2-e]pyrido[4,3-b]indoles.Anticancer Drug Des. 1998 Jun;13(4):373-86. Anticancer Drug Des. 1998. PMID: 9627674
-
β-Carbolines as potential anticancer agents.Eur J Med Chem. 2021 Apr 15;216:113321. doi: 10.1016/j.ejmech.2021.113321. Epub 2021 Feb 24. Eur J Med Chem. 2021. PMID: 33684825 Review.
-
Norharmane as a potential chemical entity for development of anticancer drugs.Eur J Med Chem. 2019 Jan 15;162:752-764. doi: 10.1016/j.ejmech.2018.11.024. Epub 2018 Nov 13. Eur J Med Chem. 2019. PMID: 30496990 Review.
Cited by
-
Preclinical and phase I trials of topoisomerase I inhibitors.Cancer Chemother Pharmacol. 1994;34 Suppl:S41-5. doi: 10.1007/BF00684862. Cancer Chemother Pharmacol. 1994. PMID: 8070026 Clinical Trial.
-
Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice.Invest New Drugs. 1993 Nov;11(4):263-77. doi: 10.1007/BF00874425. Invest New Drugs. 1993. PMID: 8157469
-
Efficient synthesis of 3H-indoles enabled by the lead-mediated α-arylation of β-ketoesters or γ-lactams using aryl azides.Org Lett. 2014 Jun 6;16(11):2916-9. doi: 10.1021/ol5010615. Epub 2014 May 27. Org Lett. 2014. PMID: 24865180 Free PMC article.
-
Discovery of benzo[e]pyridoindolones as kinase inhibitors that disrupt mitosis exit while erasing AMPK-Thr172 phosphorylation on the spindle.Oncotarget. 2015 Sep 8;6(26):22152-66. doi: 10.18632/oncotarget.4158. Oncotarget. 2015. PMID: 26247630 Free PMC article.
-
Antisense technology for cancer therapy: does it make sense?Br J Cancer. 1993 May;67(5):869-76. doi: 10.1038/bjc.1993.164. Br J Cancer. 1993. PMID: 8494718 Free PMC article. Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous